About Excelsior

We’re Rebuilding the World from the
Bottom Up: What Molecular Solution Are You Seeking?

Excelsior Sciences is leveraging a new form of chemistry that machines can do, AI can learn from, and anyone can engage. With our smart blocc platform, we’re ending chemistry’s 200-year artisanal phase and ushering in its automated era, reducing cost and complexity while making molecular solutions accessible across industries.

We are developing our own proprietary therapeutic pipeline while also collaborating with partners across industries where small molecules are key — including pharmaceuticals, materials science, and agtech. By combining proprietary chemistry with a closed-loop discovery and manufacturing platform, we enable the creation of superior small-molecule solutions and unlock new possibilities for innovation across these sectors.

Colorful geometric shapes on a black background.

We Bring Together Leading Experts in Chemistry, Computation, and Company-building

Our team has a proven, published track record advancing automated small-molecule synthesis coupled to AI to solve real-world challenges.

Mark Murcko, Ph.D.

Advisor

Sara Szymkuć, Ph.D.

Advisor

Pat Walters, Ph.D.

Advisor

David Drewry, Ph.D.

Advisor

Nessan Bermingham

Board Member

Jim Flynn

Board Member

Edward Kliphuis

Board Member

Ayome Abibi

Automation Engineer

Jeremy Ash, PhD

Machine Learning Scientist

Sigi Benjamin, PhD

Biology Lead

Kristin Burns-Huang, PhD

Project Management Lead

Olivia Goethe, PhD

Synthetic Organic Chemistry Lead

Kevin Mai, PhD

Mass Spec Specialist

Bill Motsch, PhD

Synthetic Organic Chemist

Lillian Lie, PhD

Scientific Strategy Associate

Anuj Majumber

Automation Intern

Safet Palamar

ADME Specialist

Monica Rosen

Lab Operations Manager

Christian Tapp

Automation Software Engineer

Julia Aguirre

Screening Specialist

Imani Zakiyah Davis

Executive Assistant

Benjamin Reid

Informatics Specialist

Christine Brideau

Deerfield Discovery & Development – Vice President, Preclinical Pharmacology

Jon Simansky

Deerfield Portfolio Company Operations – Operations Executive

Marissa Carnevale

Deerfield Portfolio Company Operations – Director of Talent Acquisition

Bhumika Patel

Deerfield Portfolio Company Operations – Human Resources Manager

Scientists working in a modern laboratory setting.

Support & Partnerships

Excelsior’s financing includes a $70 million Series A, co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, as well as a $25 million grant from New York’s Empire State Development. Other participants include Cornucopian Capital, Eli Lilly and Company, Illinois Ventures, and the leading academic institution, MIT.